Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 14/20 | 0.58 |
| ▸ | SLC6A2 | P23975 | 14/20 | 0.58 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.52 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.52 |
| ▸ | SLC6A4 | P31645 | 6/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.46 |
| ▸ | HTR2C | P28335 | 1/20 | 0.45 |
| ▸ | HTR2B | P41595 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19703314 | 0.88 | HTR1A (0.53) | HTR1ASLC6A2CHRNB2CHRNA4SLC6A4 | |
| SCHEMBL29994798 | 0.82 | HTR1A (0.61) | HTR1ASLC6A2CHRNB2CHRNA4SLC6A4 | |
| SCHEMBL5476116 | 0.82 | HTR1A (0.61) | HTR1ASLC6A2CHRNB2CHRNA4SLC6A4 | |
| SCHEMBL30037140 | 0.82 | CHRNB2 (0.52) | HTR1ASLC6A2CHRNB2CHRNA4SLC6A4 | |
| SCHEMBL23702833 | 0.82 | CHRNB2 (0.52) | HTR1ASLC6A2CHRNB2CHRNA4SLC6A4 | |
| SCHEMBL23702832 | 0.82 | CHRNB2 (0.52) | HTR1ASLC6A2CHRNB2CHRNA4SLC6A4 | |
| SCHEMBL26620564 | 0.82 | HTR1A (0.61) | HTR1ASLC6A2CHRNB2CHRNA4SLC6A4 | |
| SCHEMBL23703021 | 0.82 | HTR1A (0.61) | HTR1ASLC6A2CHRNB2CHRNA4SLC6A4 | |
| Hydrochloric Acid SCHEMBL5682201 | 0.81 | HTR1A (0.60) | HTR1ASLC6A2CHRNB2CHRNA4SLC6A4 | |
| Hydrochloric Acid SCHEMBL29994939 | 0.81 | HTR1A (0.60) | HTR1ASLC6A2CHRNB2CHRNA4SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1558246-B1 | PROLINE DERIVATIVES HAVING AFFINITY FOR THE CALCIUM CHANNEL ALPHA-2-DELTA SUBUNIT | PFIZER LTD (GB) | 2010-05-19 | — | — | EP | disclosed |
| US-7659305-B2 | 4-carbo- or heterocyclic alkyl-, oxy-, amino-, and thio-substituted; e.g., 2S, 4S)-4-(3-Chloro-phenoxy)-pyrrolidine-2-carboxylic acid; controlling neurotransmitter release; uses include general treatment of pain, particularly neuropathic pain. | PFIZER INC. (US) | 2010-02-09 | — | — | US | disclosed |
| EP-1558246-A1 | PROLINE DERIVATIVES HAVING AFFINITY FOR THE CALCIUM CHANNEL ALPHA-2-DELTA SUBUNIT | Pfizer Limited (GB) | 2005-08-03 | — | — | EP | disclosed |
| US-20040132801-A1 | Therapeutic proline derivatives | RAWSON DAVID JAMES (GB) | 2004-07-08 | — | — | US | disclosed |
| WO-2004039367-A1 | PROLINE DERIVATIVES HAVING AFFINITY FOR THE CALCIUM CHANNEL ALPHA-2-DELTA SUBUNIT | PFIZER LIMITED (GN) | 2004-05-13 | — | — | WO | disclosed |
| US-20020151712-A1 | 3-pyrrolidinyloxy-3'-pyridyl ether compounds useful for controlling chemical synaptic transmission | LIN NAN-HORNG (US) | 2002-10-17 | — | — | US | disclosed |
| US-20020151712-A1 | 3-pyrrolidinyloxy-3'-pyridyl ether compounds useful for controlling chemical synaptic transmission | LIN NAN-HORNG (US) | 2002-10-17 | — | — | US | disclosed |
| US-20020151712-A1 | 3-pyrrolidinyloxy-3'-pyridyl ether compounds useful for controlling chemical synaptic transmission | LIN NAN-HORNG (US) | 2002-10-17 | — | — | US | disclosed |
| EP-1212319-A2 | 3-PYRROLIDINYLOXY-3'-PYRIDYL ETHER COMPOUNDS USEFUL FOR CONTROLLING CHEMICAL SYNAPTIC TRANSMISSION | Abbott Laboratories (US) | 2002-06-12 | — | — | EP | disclosed |
| EP-1212319-A2 | 3-PYRROLIDINYLOXY-3'-PYRIDYL ETHER COMPOUNDS USEFUL FOR CONTROLLING CHEMICAL SYNAPTIC TRANSMISSION | Abbott Laboratories (US) | 2002-06-12 | — | — | EP | disclosed |
| WO-2001019817-A3 | 3-PYRROLIDINYLOXY-3'-PYRIDYL ETHER COMPOUNDS USEFUL FOR CONTROLLING CHEMICAL SYNAPTIC TRANSMISSION | ABBOTT LAB (US) | 2002-01-17 | — | — | WO | disclosed |
| WO-2001019817-A2 | 3-PYRROLIDINYLOXY-3'-PYRIDYL ETHER COMPOUNDS USEFUL FOR CONTROLLING CHEMICAL SYNAPTIC TRANSMISSION | ABBOTT LABORATORIES (US) | 2001-03-22 | — | — | WO | disclosed |
| WO-2001019817-A2 | 3-PYRROLIDINYLOXY-3'-PYRIDYL ETHER COMPOUNDS USEFUL FOR CONTROLLING CHEMICAL SYNAPTIC TRANSMISSION | ABBOTT LABORATORIES (US) | 2001-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040132801-A1 | Therapeutic proline derivatives | PRRC2C, SLC6A7, FAAH | HTR1A 58/4885SLC6A2 141/4885CHRNB2 2137/4885 |
| US-20020151712-A1 | 3-pyrrolidinyloxy-3'-pyridyl ether compounds useful for controlling chemical synaptic transmission | GAP43, SLC18A2, GABRE | HTR1A 529/4885SLC6A2 105/4885CHRNB2 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.